Crossmark

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Crossref DOI link: https://doi.org/10.1038/ng.3990

Published Online: 2017-11-06

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Blakely, Collin M

Watkins, Thomas B K

Wu, Wei

Gini, Beatrice

Chabon, Jacob J

McCoach, Caroline E

McGranahan, Nicholas

Wilson, Gareth A

Birkbak, Nicolai J

Olivas, Victor R

Rotow, Julia

Maynard, Ashley

Wang, Victoria

Gubens, Matthew A

Banks, Kimberly C http://orcid.org/0000-0002-1290-3114
Lanman, Richard B http://orcid.org/0000-0001-8122-4329
Caulin, Aleah F

St John, John

Cordero, Anibal R

Giannikopoulos, Petros

Simmons, Andrew D

Mack, Philip C

Gandara, David R

Husain, Hatim

Doebele, Robert C

Riess, Jonathan W

Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Swanton, Charles

Bivona, Trever G
License Information

Text and Data Mining valid from 2017-11-06
More Information

Article History

Received: 28 April 2017

Accepted: 12 October 2017

First Online: 6 November 2017

Competing interests

: K.C.B. and R.B.L. are employees of Guardant Health Inc.; A.F.C., J.S.J., A.R.C., and P.G. are employees of Driver Inc.; A.D.S. is an employee of Clovis Oncology Inc. T.G.B. is an advisor to Novartis, Astrazeneca, Takeda, Array Biopharma, and Revolution Medicines, and has received research funding from Ignyta and Revolution Medicines.